Skip to main content

Table 1 Pros and Cons of using each TAA in the development of CAR-T cells in prostate cancer

From: CAR-T cell therapy: a potential new strategy against prostate cancer

TAA Description Pros Cons
PSA Serine protease 1) Almost exclusively expressed by prostate epithelial cells
2) Stimulates cytotoxic lymphocytes in vivo [45]
It is a prostate-specific but not tumor-specific antigen
PAP Tyrosine phosphatase protein 1) Secreted by benign and malignant prostate cells
2) Stimulates CTLs in vivo [45]
1) More highly expressed in Gleason score 6 and 7 tumors than in higher Gleason score tumors.
2) Expressed in the placenta, kidneys and testes, and also in gastric, breast and colon cancer
PSCA Serine protease Expression increases with both high Gleason score and metastasis PSCA has also been found expressed in other cancer types
PSMA Transmembrane protein Enhances cytokine production Also expressed in low levels in salivary glands, brain and kidneys
EpCAM Transmembrane protein Show significance as a biomarker for early cancer development Not a prostate cancer- specific antigen
  1. Abbreviations: TAA tumor associated antigen, PSA prostate-specific antigen, PAP prostatic acid phosphatase, PSCA prostate stem cell antigen, PSMA prostate-specific membrane antigen, EpCAM epithelial cell adhesion molecule precursor